The purpose of this study was to examine the in-hospital outcome and influence of glycoprotein (GP) IIb/IIIa antagonists on patients with acute coronary syndromes (ACS) across a range of renal function. BACKGROUND Recent studies demonstrate increasing cardiovascular risk with progressive renal dysfunction.
Cardiovascular disease represents the most important cause of death among patients with end-stage renal disease (1) . Recent studies on patients with lesser degrees of renal dysfunction have also demonstrated increased cardiovascular risk (2) (3) (4) (5) (6) (7) (8) (9) , with predictive indices from large acute myocardial infarction (MI) registries showing renal insufficiency to be a risk factor for adverse outcome in patients admitted for acute MI (10) . Despite this increased risk, clinical trials
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examining cardiovascular morbidity and mortality associated with renal dysfunction excluded patients with more severe degrees of renal dysfunction (11) (12) (13) . Moreover, these studies preceded the era of recent therapeutic advances in the management of patients with acute coronary syndromes (ACS), including newer antithrombotic agents such as glycoprotein (GP) IIb/IIIa receptor antagonists, which have been shown to improve clinical outcome for the general population (14, 15) . Previous clinical trials investigating GP IIb/IIIa receptor antagonists have excluded patients with renal dysfunction or failure (16, 17) . Therefore, it is not clear if this patient subgroup derives the same therapeutic benefit from GP IIb/IIIa receptor antagonists as patients with normal renal function. Accordingly, we sought to examine the impact of the range of renal dysfunction on cardiovascular outcomes for all patients presenting with an ACS and determine the safety and efficacy of GP IIb/IIIa receptor antagonist use on the clinical outcomes of ACS patients with impaired renal function.
METHODS

Study population.
Patients with an ACS enrolled in the database of the Michigan Cardiovascular Outcomes Research and Reporting Program (MCORRP) between January 1999 and May 2000 were included in this study. The objective of this program is to collect clinical information for various cardiovascular diseases, utilize this information to estimate risk-adjusted outcomes, and provide confidential feedback to physicians regarding their individual performance measures. This is done with an ultimate goal of improving outcomes of all patients with cardiovascular disease admitted to the University of Michigan Medical Center with ACS. Patients were identified prospectively, whereas data on more than 30 variables including patient demographics, history, in-hospital management, and clinical events were collected retrospectively using standardized data definitions. Entry criteria for the database included patients over the age of 18 years and a presenting event not precipitated or accompanied by a significant comorbidity. Additionally, patients fulfilled criteria for unstable angina or acute MI utilizing the American College of Cardiology/ American Heart Association (ACC/AHA) criteria for data definition (18) . Following institutional review, informed consent was waived, as there were no experimental interventions and patient confidentiality was guaranteed by the study protocol. In order to guarantee rigorous data quality, each submitted data record was reviewed for completeness and face validity. All in-hospital deaths were directly audited. Definitions. Standard ACC/AHA criteria were utilized for data definition (18) . Baseline creatinine clearance (CrCl) was calculated for all patients according to the CockcroftGault formula (19) 
Female gender adjustment was calculated by multiplying the result by 0.85. Renal insufficiency was defined as a calculated CrCl Ͻ60 cc/min at the time of presentation, according to guidelines established by the National Kidney Foundation (20) . Creatinine clearance was used to categorize patients into five strata: 1) Ն90 cc/min; 2) 60 to 89 cc/min; 3) 30 to 59 cc/min; 4) Ͻ30 cc/min, but not dialysis requiring; and 5) dialysis requiring. Major bleeding events were defined according to criteria developed by the Global Use of Strategies To Open occluded arteries (GUSTO) study group and included intracranial bleeding, substantial hemodynamic compromise requiring treatment, or need for blood transfusion (21) . Death from any cause was recorded as an in-hospital mortality.
Statistical analysis. Continuous data are expressed as mean Ϯ SD and categorical data as frequencies and percentages. Student t test was used to compare continuous variables and chi-squared analysis was used to compare categorical and dichotomous variables. Odds ratios (ORs) are given with 95% confidence intervals (CIs) and p values. P values Ͻ0.05 were considered significant. Tests for associative trends with increasing severity of renal insufficiency were performed using the Mantel-Haenszel chi-squared test. Predictors for in-hospital mortality were identified using univariate analysis. In addition, variables previously reported as risk factors for 30-day mortality after acute MI based on prior studies were identified (10) . A multivariate logistic regression prediction model was developed utilizing both the variables found to show marginal association in univariate analysis (p Ͻ 0.20) and groups of previously known predictor variables. Interactions were checked for in the final model and none were found. The predictive accuracy of the multivariate logistic regression model was assessed by using the area under the receiver operating characteristic curve analysis (22) . Statistical analysis was performed using SAS software version 8.2 (SAS Institute, Cary, North Carolina).
RESULTS
Demographics and missing data. A total of 925 patients were admitted with a diagnosis of an ACS. Data on patient weight, necessary for calculation of CrCl, were missing on 36 patients, leaving 889 patients for the analysis. Of the 36 patients with missing weight data, there were 3 in-hospital deaths; 2 of the 3 patients who died in this group had a serum creatinine Ͼ1.5 mg/dl (2.1 and 2.8 mg/dl). Of the 889 patients with complete data, 178 patients suffered a Q-wave MI, 293 patients had a non-Q-wave MI, and those remaining had unstable angina. Renal insufficiency was present in 310 of 889 patients (34.9%). Patients with renal insufficiency were older, with a greater prevalence of hypertension, congestive heart failure, previous MI, peripheral vascular disease, and lower left ventricular ejection fractions compared with those without renal insufficiency (Table 1) . Outcomes in patients with renal insufficiency. Overall, there were 40 in-hospital deaths, predominantly due to arrhythmic causes (n ϭ 21) and cardiogenic shock (n ϭ 13) (Fig. 1) . Patients with renal insufficiency tended to have a longer hospital length of stay, with a higher incidence of non-Q-wave MI, and were less likely to receive percutaneous coronary intervention (PCI). In-hospital mortality was significantly higher in patients with renal insufficiency compared to those without (8.1% vs. 2.6%, p Ͻ 0.001) ( Table 2 ). Utilization of both diagnostic coronary angiography (p Ͻ 0.001, chi-square ϭ 25.0) and PCI (p Ͻ 0.001, chi-square ϭ 24.5) decreased significantly with worsening CrCl stratum, with the exception of the group of patients that were dialysis requiring. Utilization of coronary artery 
DISCUSSION
This study demonstrates that varying degrees of renal dysfunction are not uncommon among patients presenting with ACS, and shows that patients with renal dysfunction have a greater in-hospital mortality risk approaching that observed in patients with end-stage renal disease (1). Importantly, this relationship is linear and inverse such that in-hospital mortality increases as CrCl worsens. The increased mortality risk seen in patients with renal insufficiency persists after adjustment for baseline differences in clinical characteristics, suggesting that associated comorbid conditions explain only a part of the mortality risk with renal insufficiency and that it is a strong independent predictor of adverse in-hospital events. ACS and renal dysfunction. Our data corroborate the findings of other previous investigations. In 3,837 post-MI patients from the Beta-blocker Heart Attack Trial (BHAT), patients with a serum creatinine Ͼ1.0 mg/dl had an increase in overall mortality (8) . In a post-hoc analysis of 417 MI survivors from the Program on Surgical Control of Hyperlipidemias (POSCH) trial, each with 0.1 mg/dl increment in the baseline serum creatinine, the relative risk for overall mortality increased by 36% and the relative risk for atherosclerotic heart disease mortality increased by 47% (11) . A recent single-center study of 1,724 patients with ST-segment elevation MI over an eight-year period demonstrated an early mortality hazard for patients with renal dysfunction not requiring dialysis compared with patients having normal renal function, with graded increases in mortality seen as renal function declined (7) . In a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial, patients with a serum creatinine between 1.4 and 2.3 mg/dl were divided into quartiles of serum creatinine concentration. There was an incremental increase in the combined primary end point of cardiac mortality, acute MI, or stroke compared with patients having a serum creatinine Ͻ1.4 mg/dl. Patients with serum creatinine Ͼ2.3 mg/dl were excluded from entry into the HOPE trial (12). Evidence from major risk prediction indices in acute MI mortality has also suggested the importance of renal insufficiency. Clinical surrogates for renal dysfunction have been anterior or lateral location of MI, 4) systolic blood pressure, 5) white blood cell count, 6) congestive heart failure, and 7) serum creatinine. Of these variables, serum creatinine (adjusted OR 2.06, 95% CI 1.98 to 2.14) was second only to presentation in cardiac arrest for the prediction of 30-day mortality. In the same paper, six other mortality risk prediction models were reviewed. A prior history of chronic renal failure, blood urea nitrogen level, or serum creatinine was included as a predictor in five of the six models (10). Our study differs from these other investigations in several aspects. Although most of these investigations were based on data from randomized clinical trials with obligatory patient exclusion criteria, the present study utilized data from consecutive patients and looked specifically at the influence of renal insufficiency in ACS. Utilization of routine diagnostics and therapeutics in ACS. Utilization of both diagnostic coronary angiography and PCI decreased significantly as renal function declined.
Other studies have demonstrated similar findings (7), and are not surprising given that complications from these procedures are increased in the presence of renal dysfunction. Coronary angiography and percutaneous revascularization in the setting of renal dysfunction is a predictor for developing worsening nephropathy or need for dialysis support post-angiography and carries significantly increased in-hospital mortality risk (23) (24) (25) (26) (27) (28) . Despite this, there is a paucity of other therapeutic options for coronary revascularization; therefore, PCI may provide an advantageous risk-to-benefit ratio in patients with concurrent renal dysfunction despite patient comorbidities. Surgical revascularization has been associated with an increased risk for mortality over percutaneous revascularization in patients with renal dysfunction (29 -31) . The ACC/AHA guidelines for coronary artery bypass grafting surgery suggest that older patients with an elevated preoperative creatinine are at extreme risk of dialysis dependence and should be considered for alternative options such as PCI (32) . GP IIb/IIIa receptor antagonist use. In this study, the use of GP IIb/IIIa receptor antagonists decreased as renal function declined, suggesting that physicians were more apprehensive for fear of causing increased bleeding. Importantly, although our findings support the concern for increased bleeding events, the in-hospital mortality rate was not adversely affected by the use of GP IIb/IIIa receptor antagonists. After controlling for the degree of renal dysfunction, the mortality-protective benefit of GP IIb/IIIa receptor antagonists was still present. Because of the increased risk burden of cardiovascular morbidity in this population, the incremental benefit of GP IIb/IIIa receptor antagonist use may outweigh potential adverse effects and may not support a reduced use of these agents with worsening renal function. Rather, a more clear understanding of the alteration of the therapeutic effect and optimal dosing is necessary to maximize clinical benefit. Investigations on the therapeutic efficacy and clinical outcome after administration of GP IIb/IIIa receptor antagonists in patients with renal dysfunction are limited. (45) . In a phase I study of lamifiban specifically addressing renal function, 20 patients were stratified by CrCl into three groups: 1) no renal impairment, 2) mild-to-moderate renal impairment, and 3)severe renal impairment). The mean plasma concentration necessary to inhibit platelet aggregation by 50% ex vivo was reduced only in the severe renal impairment group (CrCl Ͻ29 cc/min). In this group, platelet recovery time was prolonged fourfold compared with subjects with mild-to-moderate or no renal impairment (46) . In the clinical setting, recent retrospective studies examining the usage of GP IIb/IIIa receptor antagonists in patients with renal dysfunction have demonstrated clinical benefit (47, 48) . However, as noted previously, the PRISM studies excluded patients with moderate-to-severe renal dysfunction. This suggests the need for further investigations and perhaps targeted clinical trials to assess the clinical benefit and optimal dosing of GP IIb/IIIa receptor antagonists in patients with renal insufficiency. Clinical implications. Although the mechanism of increased mortality risk for mortality after ACS in patients with renal insufficiency is not entirely clear, recognition of the increased mortality risk burden of patients with renal dysfunction is crucial. Coexisting conditions and comorbidities such as volume overload, diabetes mellitus, congestive heart failure (systolic and diastolic), hypoalbuminemia, anemia, and older age may contribute (49) . In addition, studies in this population have indicated more unfavorable lipid profiles, chronic inflammatory conditions, elevated homocysteine, aggressive atherosclerosis, endothelial dysfunction, and altered cytokine levels (50 -54) . Abnormal drug pharmacokinetics in these patients may further contribute to increased risk. The specific contribution of each of the above factors to the greater morbidity and mortality risk needs to be addressed in future studies. Although investigations suggest that the benefit-to-risk ratio of various therapeutic interventions is increased for patients at highest risk of adverse events, this needs to be proven in future studies. Until such data are available, physicians should continue to use their best judgment in patient management while at the same time not depriving appropriate patients of newer treatment strategies, such as GP IIb/IIIa receptor antagonists, that may improve clinical outcome.
Study limitations.
The results from this study may not be applicable to patients at nonteaching, non-tertiary care facilities. This was an observational study and is prone to the limitations inherent in such evaluations. Renal insufficiency 
Conclusions.
Renal dysfunction is present in a substantial proportion of patients with acute coronary syndromes, and, in non-dialysis-dependent patients with worsening renal dysfunction, there is an associated incremental increase in risk of in-hospital adverse outcomes. Recognition of the risk burden of renal dysfunction is essential for risk stratification and may assist in development of management strategies tailored to improve outcome, including appropriate utilization of cardiovascular diagnostic tests and therapeutics used in current cardiovascular care. In this study, GP IIb/IIIa receptor antagonist use was not associated with increased mortality risk in the setting of concurrent renal insufficiency. Additional investigations are necessary to assess optimal dosing of GP IIb/IIIa receptor antagonists for maximization of clinical benefit in this high-risk cohort.
